Containing contraceptive costs

Abstract

The cost of the newer hormone-based long-acting reversible contraceptive (LARC) methods, which are most effective in preventing unwanted pregnancy because their use does not demand daily compliance, is still high. The author suggests that the lifespan of these products is longer than their licence dictates. Clinicians should use their clinical judgement, replacing the device for users who seem concerned, and supporting users who request extended use. He concludes that cheaper and longer-acting hormonal LARC methods are on the way.